ADMA Biologics (NASDAQ:ADMA) Stock Price Down 8.8% – Time to Sell?

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) dropped 8.8% on Monday . The company traded as low as $16.76 and last traded at $16.93. Approximately 554,779 shares traded hands during trading, a decline of 71% from the average daily volume of 1,946,501 shares. The stock had previously closed at $18.56.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several recent research reports. Raymond James increased their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Finally, HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Trading Down 1.0 %

The firm has a market capitalization of $3.86 billion, a price-to-earnings ratio of 58.29 and a beta of 0.76. The business’s 50-day moving average price is $19.29 and its 200 day moving average price is $17.23. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. During the same period in the prior year, the company posted $0.01 EPS. On average, equities analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Activity

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors have recently modified their holdings of the stock. Rhumbline Advisers lifted its holdings in ADMA Biologics by 5.4% during the 2nd quarter. Rhumbline Advisers now owns 310,539 shares of the biotechnology company’s stock worth $3,472,000 after buying an additional 15,844 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of ADMA Biologics by 192.6% in the second quarter. Victory Capital Management Inc. now owns 84,046 shares of the biotechnology company’s stock valued at $940,000 after purchasing an additional 55,322 shares during the period. Acadian Asset Management LLC bought a new stake in ADMA Biologics during the 2nd quarter valued at $93,000. Quest Partners LLC bought a new stake in shares of ADMA Biologics during the second quarter valued at about $29,000. Finally, State of New Jersey Common Pension Fund D acquired a new stake in shares of ADMA Biologics in the 2nd quarter worth approximately $2,212,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.